Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.43
$0.252.72%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 112.88M | -10.48M | -26.43M | -25.70M | -26.37M |
Total Depreciation and Amortization | 477.00K | 526.00K | 540.00K | 548.00K | 563.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 6.86M | 6.94M | 7.52M | 7.70M | 5.94M |
Change in Net Operating Assets | 11.61M | -20.18M | -3.24M | -30.00K | -4.69M |
Cash from Operations | 131.83M | -23.19M | -21.62M | -17.48M | -24.57M |
Capital Expenditure | -152.00K | -42.00K | -103.00K | -46.00K | -12.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 13.78M | 861.00K | -29.90M | -88.23M | 10.00M |
Cash from Investing | 13.63M | 819.00K | -30.00M | -88.28M | 9.99M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 1.37M | 568.00K | 8.16M | 120.65M | 1.72M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 1.37M | 568.00K | 8.16M | 120.65M | 1.72M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 146.83M | -21.81M | -43.46M | 14.90M | -12.86M |